AI
Thursday, December 29, 2005 10:51:11 AM
Wow, look who's back ... good to see you again. Here is a repost from RB ... they usually have such crap over there, but this was a repost that merits an additional reposting ...
By: stervc
28 Dec 2005, 12:36 PM EST
Msg. 292876 of 292987
(This msg. is a reply to 292837 by stervc.)
Jump to msg. #
Some Quick CYGX Thoughts & DD...
Authorized Shares (AS) = 300,000,000
Outstanding Shares (OS) = 119,162,970
Restricted Shares = 44,526,371
Float = 74,636,599
Website for CYGX:
http://www.cytogenix.com/
Website for GE Healthcare:
http://www.gehealthcare.com/usen/index.html
CYGX started out in the molecular medicine arena with their primary product being one to cure Herpes 1 and 2 complexes. Well, Herpes can’t be cured, but it can become stagnant to where it’s placed in a dormant stage.
It was discovered that their product was successful for creating a vaccine for stagnating the spreading of sepsis, which is a condition caused by the presence of microorganisms or their toxins in the tissue or the bloodstream. Sepsis is what causes people to get staff infections in the operating rooms amongst many other fatal things. Sepsis has mortality rates ranging from 30% to 50% and is the most common cause of death in the noncardiac intensive care units.
The department of GE that deals with CYGX, GE Healthcare, is in the Homeland Security arena where they have teamed together to create vaccines. The recent contract with GE is really a multi-million dollar contract that doesn’t have a figure on it because it’s really like a blank check that has been fronted to CYGX to conduct research.
GE Healthcare fronts the cash while CYGX performs all of the research to create vaccines for a variety of potential medicines. The amount of the contract is unknown because of the amount and types of research being unknown until completed.
Since GE Healthcare is a $14 billion unit of General Electric Company (NYSE:GE), it is probably easy to see why money might not be an issue to front this type of research. This will automatically put GE ahead and/or further ahead of all of their competitors in my opinion.
Anti-viral and DNA is needed to be used as a base for running tests for all types of cures and vaccines in the biotech world. CYGX can accommodate companies in this area.
DNA costs $300,000 per gram because of the fermentation process as the bulk of the cost goes toward disposing of dead cells because of the way they have to be disposed of.
CYGX has created a synthetic process where synthetic DNA is created and used to eliminate the need for having a fermentation process. Because of such, this creates huge savings for major biotech companies to perform research.
From these tests, vaccines can now be made. I would like to think that companies on the line of Pfizer and others will eventually want a piece of this technology that CYGX has to offer. This is definitely next generation technology and we are becoming made aware of it before it really kicks off in my opinion. In my opinion, this will be huge!
Currently, CYGX is trading on the OTCBB. I think that the company will steer away from the NASDAQ because of the shorting and naked shorting that the company’s stock could become victim to. It is my understandings that they probably would much rather consider pursuing trading on the AMEX where it’s an auction market. This means that the “Bid” and “Ask” sizes can be reflected more accurately and have less opportunity for any kind of shorting or naked shorting. It will strictly trade on actual and factual “supply versus demand” principles.
From doing my quick DD on CYGX, I had to ignore that the company has a negative EPS and realize that people do buy stocks because of their Earnings, but people buy stocks too because of their “potential” for “future” Earnings. Because of this, I think that CYGX is one of the best mid to long term stocks out there that I think will have an outstanding future. These are only my opinions. I hope this helps!
All is well!
http://www.sterlingsclass.com/
Sterling
By: stervc
28 Dec 2005, 12:36 PM EST
Msg. 292876 of 292987
(This msg. is a reply to 292837 by stervc.)
Jump to msg. #
Some Quick CYGX Thoughts & DD...
Authorized Shares (AS) = 300,000,000
Outstanding Shares (OS) = 119,162,970
Restricted Shares = 44,526,371
Float = 74,636,599
Website for CYGX:
http://www.cytogenix.com/
Website for GE Healthcare:
http://www.gehealthcare.com/usen/index.html
CYGX started out in the molecular medicine arena with their primary product being one to cure Herpes 1 and 2 complexes. Well, Herpes can’t be cured, but it can become stagnant to where it’s placed in a dormant stage.
It was discovered that their product was successful for creating a vaccine for stagnating the spreading of sepsis, which is a condition caused by the presence of microorganisms or their toxins in the tissue or the bloodstream. Sepsis is what causes people to get staff infections in the operating rooms amongst many other fatal things. Sepsis has mortality rates ranging from 30% to 50% and is the most common cause of death in the noncardiac intensive care units.
The department of GE that deals with CYGX, GE Healthcare, is in the Homeland Security arena where they have teamed together to create vaccines. The recent contract with GE is really a multi-million dollar contract that doesn’t have a figure on it because it’s really like a blank check that has been fronted to CYGX to conduct research.
GE Healthcare fronts the cash while CYGX performs all of the research to create vaccines for a variety of potential medicines. The amount of the contract is unknown because of the amount and types of research being unknown until completed.
Since GE Healthcare is a $14 billion unit of General Electric Company (NYSE:GE), it is probably easy to see why money might not be an issue to front this type of research. This will automatically put GE ahead and/or further ahead of all of their competitors in my opinion.
Anti-viral and DNA is needed to be used as a base for running tests for all types of cures and vaccines in the biotech world. CYGX can accommodate companies in this area.
DNA costs $300,000 per gram because of the fermentation process as the bulk of the cost goes toward disposing of dead cells because of the way they have to be disposed of.
CYGX has created a synthetic process where synthetic DNA is created and used to eliminate the need for having a fermentation process. Because of such, this creates huge savings for major biotech companies to perform research.
From these tests, vaccines can now be made. I would like to think that companies on the line of Pfizer and others will eventually want a piece of this technology that CYGX has to offer. This is definitely next generation technology and we are becoming made aware of it before it really kicks off in my opinion. In my opinion, this will be huge!
Currently, CYGX is trading on the OTCBB. I think that the company will steer away from the NASDAQ because of the shorting and naked shorting that the company’s stock could become victim to. It is my understandings that they probably would much rather consider pursuing trading on the AMEX where it’s an auction market. This means that the “Bid” and “Ask” sizes can be reflected more accurately and have less opportunity for any kind of shorting or naked shorting. It will strictly trade on actual and factual “supply versus demand” principles.
From doing my quick DD on CYGX, I had to ignore that the company has a negative EPS and realize that people do buy stocks because of their Earnings, but people buy stocks too because of their “potential” for “future” Earnings. Because of this, I think that CYGX is one of the best mid to long term stocks out there that I think will have an outstanding future. These are only my opinions. I hope this helps!
All is well!
http://www.sterlingsclass.com/
Sterling
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
